ORIC — ORIC Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $1.19bn
- $907.24m
- 45
- 21
- 68
- 41
Annual income statement for ORIC Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 74.2 | 78.9 | 91.8 | 111 | 143 |
| Operating Profit | -74.2 | -78.9 | -91.8 | -111 | -143 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -73.7 | -78.7 | -89.1 | -101 | -128 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -73.7 | -78.7 | -89.1 | -101 | -128 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -73.7 | -78.7 | -89.1 | -101 | -128 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -73.7 | -78.7 | -89.1 | -101 | -128 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.23 | -2.07 | -2.12 | -1.96 | -1.83 |